SPX3,647.29-7.75 -0.21%
DIA291.30-1.42 -0.49%
IXIC10,829.50+26.58 0.25%

Update: Akero Therapeutics' Efruxifermin Phase 2b Study Meets Endpoints for NASH Treatment; Shares Soar

Update: Akero Therapeutics' Efruxifermin Phase 2b Study Meets Endpoints for NASH Treatment; Shares Soar

MT Newswires · 09/13/2022 10:25

Please log in to view news